GNE Myopathy
·MeSH: Distal myopathy, Nonaka type
Prevalence
75.0 / 100K
1 drug in development·1 company·2 clinical trials
Drug Pipeline by Phase
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| ux016 | Ultragenyx Pharmaceutical Inc. (RARE) |
Frequently asked questions
How many drugs are in development for GNE Myopathy?
BioSniper tracks 1 drug in development for GNE Myopathy across 1 company.
How many clinical trials target GNE Myopathy?
There are 2 clinical trials targeting GNE Myopathy tracked by BioSniper.
What is the prevalence of GNE Myopathy?
The estimated prevalence of GNE Myopathy is approximately 75.0 per 100,000 population.
Deep-dive into GNE Myopathy
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis